In recent years, the landscape of wellness and metabolic support has shifted signi These drugs may be associated with risks of peri-operative pulmonary aspiration or euglycaemic ketoacidosis. We produced a consensus statement for the peri- ficantly due to the widespread popularity of various compounds. As a frequent user of peptide products for personal research and wellness optimization, I have become increasingly aware of how these substances interact with physiological processes, particu Chapter 24 - Peptide therapeutics in anesthesiology larly when preparing for clinical procedures. The intersection of peptides and anesthesia is a topic that demands careful attention, especially for those of us who prioritize transparency and safety in our personal health protocols.
Understanding Short-term administration of common anesthetics does not the Physiological Impact
Many individuals, myself included, utilize Glucagon-like peptide-1 (GLP-1) receptor agonists for their metabolic benefits. However, it is essential to recognize that peptides are typically used clinically as replacement therapies to regulate complex physiological processes. When discussing Medications to Stop Before Surgery the relationship between these compounds and surgical safety, the primary concern revolves around their pharmacodynamics.
These molecules exert very potent gastric slowing effects, a mechanism that is highly effective for metabolic goals but potentially problematic in a surgical context. Because Glucagon-like peptide-1 (GLP-1) agonists delay gastric emptying, they can lead to a scenario where the stomach contains high volumes of complex contents even after a patient has adhered to standard fasting protocols. This creates an increased risk of pulmonary aspiration during sedation or anaesthesia.
Analyzing Guidelines and Best Practices
The discourse surrounding anesthesia safety is constantly evolving. In my research, I have noted that the guidance for stopping glucagon-like peptide-1 (GLP-1) agonists is far from static. While some clinicians suggest discontinuing GLP-1 agonists a week before surgery, other emerging reports recommend stopping GLP-1 agonists 14 days before total joint arthroplasty or other major procedures to mitigate potential complications.
Conversely, there is a nuanced shift in the medical community. Some updated consensus statements suggest that most patients should not stop taking GLP-1 receptor agonists prior to elective surgery, provided they are managed correctly. This highlights why it is vital to learn about the crucial GLP-1 medication disclosure before anesthesia. Failing to provide this information to your care team may increase risks in surgery, as the primary danger—undigested gastric content—i Safe anesthesia requires an empty stomach whenever possible. B. SGLT2 Inhibitors Examples: Empagliflozin – Brand: Jardiance; Canagliflozin – Brand: Invokana s often silent until the moment of intubation.
Peptides Beyond Metabolic Agonists
It is important to distinguish between different classes of research compounds. While GLP-1 RAs are the focus of current surgical scrutiny, other substances like BPC-157 (a pentadecapeptide) are frequently discussed in biohacking communities. Research indicates that certain compounds, such as the peptide BPC-157, have been studied for their ability to influence local tissue responses. However, one must co Apr 1, 2025 — As such, patients taking GLP-1 receptor agonists may have an increased risk of aspiration of gastric contents during sedation and anesthesia. nsider that anesthetic use during research experiments may alter the concentration or the enzymatic processing of peptides bein ASA Advises No Longer Holding GLP-1 Agents Prior to g measured, which could obscure results or affect the intended physiological outcome.
Final Considerations for Personal Safety
For those of us managing our own wellness protocols, the following takeaways remain paramount:
* Full Disclosure: Always maintain an accurate record of all supplements and peptides. If you are taking Glucagon-like peptide-1 receptor agonists, this must be communicated clearly.
* Stay Informed: Guidelines such as the ASA guidelines are updated frequently. What was standard in 2024 may be refined by 2026.
* Risk Mitigation: The goal of any anest Glucagon-Like Peptide 1 Receptor Agonists and Aspiration hetic considerations for patients taking Glucagon-like peptide-1 agonists is to ensure the stomach is empty. If you are unsure about your specific protocol, consult with professionals who are up to date on these specific metabolic interactions.
By staying vigilant and prioritizing clear communication, we can continue to explore the benefits of these compounds while ensuring that we are fully prepared for any clinical encounters. The key is to view our health protocols through a lens of total transparency, especially when external stressors like surgery are introduced.